Bio Business

» tuberculosis, nonprofit and regulation

Most Recent

image: Picking Up the Pace

Picking Up the Pace

By | January 1, 2016

FDA designations promise to expedite the approval of drugs for conditions ranging from infectious disease to cancer.

0 Comments

image: Battling the Bulge

Battling the Bulge

By | November 1, 2015

Weight-loss drugs that target newly characterized obesity-related receptors and pathways could finally offer truly effective fat control.

0 Comments

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

image: That Loving Feeling

That Loving Feeling

By | July 1, 2014

There are no FDA-approved drugs to treat low sexual desire in women, but not for lack of trying.

1 Comment

image: Outwitting the Perfect Pathogen

Outwitting the Perfect Pathogen

By | January 1, 2014

Tuberculosis is exquisitely adapted to the human body. Researchers need a new game plan for beating it.

0 Comments

image: How Safe Is Your Medicine Cabinet?

How Safe Is Your Medicine Cabinet?

By | May 1, 2013

After numerous high-profile safety scares, clinicians and regulators push to fix critical weaknesses in the FDA’s monitoring system for approved drugs.

1 Comment

image: Biology Hacklabs

Biology Hacklabs

By | March 1, 2013

Fueled by donations, sweat, and occasional dumpster diving, community laboratories for DIY biologists are cropping up around the country.

2 Comments

image: Bioterrorist Battles

Bioterrorist Battles

By | January 1, 2012

A Swiss-based firm may have a back-door way to thwart a bioterrorist attack—by fighting the flu.

9 Comments

image: Take Two of These

Take Two of These

By | June 22, 2011

Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.

3 Comments

image: The Profits of Nonprofit

The Profits of Nonprofit

By | January 1, 2011

The surprising results when drug development and altruism collide

9 Comments

Popular Now

  1. What Budget Cuts Might Mean for US Science
    News Analysis What Budget Cuts Might Mean for US Science

    A look at the historical effects of downsized research funding suggests that the Trump administration’s proposed budget could hit early-career scientists the hardest.  

  2. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  3. Opinion: On “The Impact Factor Fallacy”
  4. Unstructured Proteins Help Tardigrades Survive Desiccation
Business Birmingham